This week’s OIS Retina Podcast guest is French-born Patricia Zilliox, who boomeranged back to her homeland to become president and CEO of Eyevensys.

Before that she’d spent 25 years with Alcon before joining the Foundation Fighting Blindness as chief drug development officer. 

When a family matter brought her back to France, she was introduced to Eyevensys through the investment group BPI France. 

Having spent so much time evaluating new therapies at FFB, she was intrigued by Eyevensys’ unique platform to enable the sustained intraocular production of therapeutic proteins to treat a broad range of ophthalmic disease. 

Needless to say, she took the CEO job and shares more details on Eyevensys’ lead product: a gene therapy to treat uveitis.